Topical formulations of olopatadine for treatment of allergic or inflammatory disorders of the eye and nose are disclosed. The aqueous formulations contain approximately 0.17-0.62% (w/v) of olopatadine and an amount of polyvinylpyrrolidone or polystyrene sulfonic acid sufficient to enhance the physical stability of the formulations.

 
Web www.patentalert.com

< DNA-PK inhibitors

> Carbonyl compound containing long-chain branched alkyl group

~ 00449